The stock may re-rate on sustained organic growth, margin improvement, and strong 2026 guidance. Watch for execution on PNS product launch and cash flow conversion. Short interest could compress if momentum continues.
Price Chart
Executive Summary
Bioventus reported strong Q4 and full-year 2025 results with 10.0% organic revenue growth in Q4, GAAP profitability improvement, and raised 2026 guidance projecting 6-7% revenue growth and 7-13% adjusted EPS growth. The company exited a divestiture-impacted year with improved margins and cash flow, signaling operational strength.
Key Financial Metrics
Key Facts
- Q4 revenue: $157.9M, up 2.8% reported, 10.0% organic; driven by double-digit growth in Pain Treatments and Surgical Solutions
- Q4 GAAP EPS: $0.21 vs. $0.00 in prior year; Non-GAAP EPS: $0.24 vs. $0.26 in prior year
- Full-year 2025 revenue: $568.1M, down 0.9% reported (due to divestiture), up 7.5% organically
- Full-year 2025 GAAP EPS: $0.33 vs. loss of $0.56; Adjusted EPS: $0.68, up 21.4% YoY
- 2026 guidance: Revenue $600M–$610M (~6-7% growth), Adjusted EPS $0.73–$0.77 (~7-13% growth), CFO: $82M–$87M
- Q4 cash from operations: $38.0M, up 97% YoY; full-year CFO up 92%
- Reduced debt by $29M in Q4, strengthened balance sheet
Financial Impact
Revenue growth accelerating organically, earnings normalized to profitability, and 2026 guidance implies continued margin expansion. $32M+ increase in annual revenue guidance and ~$0.05 EPS uplift projected.
Risk Factors
- Adjusted EPS declined slightly YoY despite revenue and operating income growth, due to tax headwinds
- Restorative Therapies segment still under pressure post-divestiture, though EXOGEN showing organic recovery
- Forward guidance excludes GAAP net income, limiting visibility on full profitability trajectory
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3249987 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 15, 2026 6w ago | Institutional Cluster | $13.88 $13.16 | ▼ −5.19% | ▼ −3.66% | $13.13 (−5.40%) |
Aug 5, 2026 8w ago | 8-K | $15.26 $14.37 | ▼ −5.83% | ▼ −5.23% | $13.13 (−13.96%) |
Aug 5, 2026 8w ago | Press Release | $15.26 $14.37 | ▼ −5.83% | ▼ −5.23% | $13.13 (−13.96%) |
Jun 11, 2026 16w ago | Institutional Cluster | $8.68 $12.22 | ▼ −40.78% | ▼ −38.89% | $13.13 (−51.27%) |
Jun 2, 2026 17w ago | Press Release | $8.11 $9.85 | ▼ −21.45% | ▼ −23.02% | $13.13 (−61.90%) |
May 21, 2026 19w ago | 8-K | $9.28 $8.99 | ▼ −3.13% | ▼ −1.71% | $13.13 (+41.49%) |
May 8, 2026 21w ago | Court Ruling | $10.50 $9.04 | ▼ −13.90% | ▼ −13.93% | $13.13 (+25.05%) |
May 6, 2026 21w ago | 8-K | $10.92 $8.55 | ▼ −21.70% | ▼ −24.48% | $13.13 (+20.24%) |
May 6, 2026 21w ago | Press Release | $10.92 $8.55 | ▼ −21.70% | ▼ −24.48% | $13.13 (+20.24%) |
Apr 28, 2026 22w ago | Press Release | $9.67 $8.87 | ▼ −8.27% | ▼ −14.32% | $13.13 (+35.78%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access